Humoral immune response to Covid-19 vaccination in patients with cancer – Results from the ANRS0001S COV-POPART study

20251 citationsJournal Articlehybrid Open Access

Authors

Liem Binh Luong Nguyen · Inserm

Lyvia Magloire · Université de Bordeaux

Alexis François · Université de Bordeaux

David Billard · Hôpital Foch

Frank Priou · Centre Hospitalier Départemental Vendée

Jennifer Arrondeau · Assistance Publique – Hôpitaux de Paris

Claude Linassier ·

Abstract

Patients with cancer have comparable response rates to controls one month and six months after a booster dose. Our results support the benefit of a booster dose in patients with cancer.

Topics & Keywords

COVID-19 and healthcare impacts SARS-CoV-2 and COVID-19 Research Lymphadenopathy Diagnosis and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Vaccine

Volume 63, pp. 127633-127633

DOI: 10.1016/j.vaccine.2025.127633

Field-Weighted Citation Impact: 1.09